Amarantus Bioscience Holdings Inc AMBS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.00
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $630.41
- Volume/Avg
- 1.2 Mil / 390,512
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Amarantus Bioscience Holdings Inc is a biopharmaceutical company. It is focused on developing therapeutic products for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology. The company's prime therapeutic program, eltoprazine is a small molecule indicated for the treatment of Levodopa-induced dyskinesia. The group's diagnostics division is dedicated to the development and commercialization of neurology diagnostic products. Its diagnostic product, LymPro Test is a blood-based assay to diagnose Alzheimer's disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 12
- Website
- http://www.amarantus.com
Valuation
|
Metric
|
AMBS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AMBS
|
|---|---|
Quick Ratio | 0.00 |
Current Ratio | 0.03 |
Interest Coverage | −4.84 |
Quick Ratio
AMBS
Profitability
|
Metric
|
AMBS
|
|---|---|
Return on Assets (Normalized) | −188.60% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
AMBS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xxzswsfdy | Vfrh | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mzycbft | Vrfmcw | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Svhmvqsr | Bljjyvy | $97.8 Bil | |
MRNA
| Moderna Inc | Qzwnvgnm | Ktjr | $41.3 Bil | |
ARGX
| argenx SE ADR | Qxtzjqxx | Pyjr | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Ycdcghm | Zdmxf | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Prbcvdhf | Tzdhhl | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pllrykxk | Bcwsjv | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xdpbtdrlr | Nmzsyc | $12.5 Bil | |
INCY
| Incyte Corp | Nklljgxm | Clnxkwv | $11.6 Bil |